262 related articles for article (PubMed ID: 19827267)
1. Human ABC transporter ABCG2 in cancer chemotherapy and pharmacogenomics.
Ishikawa T; Nakagawa H
J Exp Ther Oncol; 2009; 8(1):5-24. PubMed ID: 19827267
[TBL] [Abstract][Full Text] [Related]
2. Human ABC transporter ABCG2 in cancer chemotherapy: drug molecular design to circumvent multidrug resistance.
Ishikawa T; Saito H; Hirano H; Inoue Y; Ikegami Y
Methods Mol Biol; 2012; 910():267-78. PubMed ID: 22821599
[TBL] [Abstract][Full Text] [Related]
3. Role of the breast cancer resistance protein (ABCG2) in drug transport.
Mao Q; Unadkat JD
AAPS J; 2005 May; 7(1):E118-33. PubMed ID: 16146333
[TBL] [Abstract][Full Text] [Related]
4. [Drug resistance mediated by ABC transporters].
Yoshikawa M; Ito A; Ishikawa T; Ikegami Y
Gan To Kagaku Ryoho; 2004 Jan; 31(1):1-6. PubMed ID: 14750312
[TBL] [Abstract][Full Text] [Related]
5. Molecular pharmacology of ABCG2 and its role in chemoresistance.
Stacy AE; Jansson PJ; Richardson DR
Mol Pharmacol; 2013 Nov; 84(5):655-69. PubMed ID: 24021215
[TBL] [Abstract][Full Text] [Related]
6. Multidrug resistance in cancer chemotherapy and xenobiotic protection mediated by the half ATP-binding cassette transporter ABCG2.
Han B; Zhang JT
Curr Med Chem Anticancer Agents; 2004 Jan; 4(1):31-42. PubMed ID: 14754410
[TBL] [Abstract][Full Text] [Related]
7. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
Hu J; Zhang X; Wang F; Wang X; Yang K; Xu M; To KK; Li Q; Fu L
Oncotarget; 2015 Dec; 6(42):44643-59. PubMed ID: 26556876
[TBL] [Abstract][Full Text] [Related]
8. ABCG2: a perspective.
Robey RW; To KK; Polgar O; Dohse M; Fetsch P; Dean M; Bates SE
Adv Drug Deliv Rev; 2009 Jan; 61(1):3-13. PubMed ID: 19135109
[TBL] [Abstract][Full Text] [Related]
9. Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K/Akt signaling pathway.
Pick A; Wiese M
ChemMedChem; 2012 Apr; 7(4):650-62. PubMed ID: 22354538
[TBL] [Abstract][Full Text] [Related]
10. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
[TBL] [Abstract][Full Text] [Related]
11. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2).
Doyle L; Ross DD
Oncogene; 2003 Oct; 22(47):7340-58. PubMed ID: 14576842
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo evidence for the importance of breast cancer resistance protein transporters (BCRP/MXR/ABCP/ABCG2).
Meyer zu Schwabedissen HE; Kroemer HK
Handb Exp Pharmacol; 2011; (201):325-71. PubMed ID: 21103975
[TBL] [Abstract][Full Text] [Related]
13. Breast cancer resistance protein (BCRP/ABCG2).
Staud F; Pavek P
Int J Biochem Cell Biol; 2005 Apr; 37(4):720-5. PubMed ID: 15694832
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2.
Lepper ER; Nooter K; Verweij J; Acharya MR; Figg WD; Sparreboom A
Pharmacogenomics; 2005 Mar; 6(2):115-38. PubMed ID: 15882131
[TBL] [Abstract][Full Text] [Related]
15. Oligomerization domain of the multidrug resistance-associated transporter ABCG2 and its dominant inhibitory activity.
Xu J; Peng H; Chen Q; Liu Y; Dong Z; Zhang JT
Cancer Res; 2007 May; 67(9):4373-81. PubMed ID: 17483351
[TBL] [Abstract][Full Text] [Related]
16. A new strategy of high-speed screening and quantitative structure-activity relationship analysis to evaluate human ATP-binding cassette transporter ABCG2-drug interactions.
Saito H; Hirano H; Nakagawa H; Fukami T; Oosumi K; Murakami K; Kimura H; Kouchi T; Konomi M; Tao E; Tsujikawa N; Tarui S; Nagakura M; Osumi M; Ishikawa T
J Pharmacol Exp Ther; 2006 Jun; 317(3):1114-24. PubMed ID: 16489126
[TBL] [Abstract][Full Text] [Related]
17. Human ATP-Binding Cassette transporters ABCB1 and ABCG2 confer resistance to CUDC-101, a multi-acting inhibitor of histone deacetylase, epidermal growth factor receptor and human epidermal growth factor receptor 2.
Wu CP; Hsiao SH; Su CY; Luo SY; Li YQ; Huang YH; Hsieh CH; Huang CW
Biochem Pharmacol; 2014 Dec; 92(4):567-76. PubMed ID: 25450670
[TBL] [Abstract][Full Text] [Related]
18. Ubiquitin-mediated proteasomal degradation of non-synonymous SNP variants of human ABC transporter ABCG2.
Nakagawa H; Tamura A; Wakabayashi K; Hoshijima K; Komada M; Yoshida T; Kometani S; Matsubara T; Mikuriya K; Ishikawa T
Biochem J; 2008 May; 411(3):623-31. PubMed ID: 18237272
[TBL] [Abstract][Full Text] [Related]
19. Emerging new technology: QSAR analysis and MO Calculation to characterize interactions of protein kinase inhibitors with the human ABC transporter, ABCG2 (BCRP).
Saito H; An R; Hirano H; Ishikawa T
Drug Metab Pharmacokinet; 2010; 25(1):72-83. PubMed ID: 20208390
[TBL] [Abstract][Full Text] [Related]
20. QSAR analysis and molecular modeling of ABCG2-specific inhibitors.
Nicolle E; Boumendjel A; Macalou S; Genoux E; Ahmed-Belkacem A; Carrupt PA; Di Pietro A
Adv Drug Deliv Rev; 2009 Jan; 61(1):34-46. PubMed ID: 19135106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]